PDCD1 and lung cancer: Although immunotherapy targeting PD-L1/PD-1 signaling is being used for treatment of advanced lung cancers, the benefit is limited to the early stages, because antibody-based checkpoint inhibitors are associated with unique immune-related adverse effects and high costs [4].